SVF
Level C· Early Human ResearchRetrospective Study

Injection of Adipose-Derived Stromal Vascular Fraction Rapidly Relieves Pain in Patients with Knee Osteoarthritis.

Kim YS., Suh DS., Kwon YB., Chung JH., Koh YG.

Retrospective Study with a reported sample of 146 on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, Chronic Inflammation, published in Medicina (Kaunas) (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Medicina (Kaunas) (2026)
Country
Switzerland
Reported sample size
146
PMID
41752807
DOI
10.3390/medicina62020409

Abstract (original English)

Background and Objectives : Intra-articular injection of adipose-derived stromal vascular fraction (SVF) has emerged as a promising regenerative treatment for knee osteoarthritis (OA) because of its heterogeneous cellular composition and potent anti-inflammatory paracrine effects. Although SVF therapy has demonstrated clinical efficacy, the timing of pain relief and the influence of SVF cell dose on early clinical outcomes remain incompletely defined. Materials and Methods : This retrospective study included 146 patients (217 knees) with Kellgren-Lawrence (K-L) grade II-IV knee OA who underwent intra-articular injection of autologous adipose-derived SVF and completed a minimum follow-up of 1 year. Pain was assessed using the visual analog scale (VAS), and patients reported the time to perceived pain improvement after treatment. Radiographic severity was evaluated using the K-L grading system. Correlation analyses were performed to assess associations between pain-related outcomes, SVF cell number, and radiographic severity. Results : VAS scores improved significantly from baseline to the final follow-up ( p < 0.01). Patients reported perceived pain improvement at a mean of 18.9 ± 14.5 days after SVF injection. The mean injected dose was 7.4 × 10 7 total SVF cells per knee, including approximately 7.0 × 10 6 stromal cells. Higher SVF cell numbers were significantly associated wi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples, often without a control group.

How we grade evidence
HumansOsteoarthritis, KneeFemaleMaleInjections, Intra-ArticularRetrospective StudiesMiddle AgedAgedAdipose TissuePain Measurement
KneeHipKnee OsteoarthritisOsteoarthritisCartilage DamageChronic Inflammation
View on PubMedDOI

Related research